| INSULIN GLARGINE
Lantus, Lantus SoloStar
Classifications: hormone; antidiabetic agent; insulin long-acting; Therapeutic: antidiabetic; insulin long-acting
Prototype: Insulin injection
Pregnancy Category: C
100 U/mL injection; 3 mL cartridge; Prefilled, disposable pen
A recombinant human insulin analog with a long duration of action. Lowers blood glucose levels over an extended period of
time by stimulating peripheral glucose uptake especially in muscle and fat tissue. In addition, insulin inhibits hepatic
Lowers blood glucose levels over an extended period of time. It also prevents the conversion of glucagon to glucose in the
Bedtime dosing of adults and children with type 1 diabetes, or adults with type 2 diabetes.
Prior hypersensitivity to insulin glargine; hypoglycemia; pregnancy (category C). Safety and efficacy in children with type
2 diabetes are unknown.
Renal and hepatic impairment; lactation. Safety and efficacy in children <6 y of age in type 1 diabetes.
Route & Dosage
|Type 1 Diabetes
Adult/Child: SC If not taking insulin, give 10 U at same time each day (usually at bedtime) once daily; if taking NPH or ultralente insulin once daily, give same dose at same time each day (usually at bedtime); if taking NPH insulin twice daily, give 80%
of total daily dose at same time each day (usually at bedtime)
Type 2 Diabetes
Adult: SC If already taking oral hypoglycemic drugs, start with 10 U at same time each day (usually at bedtime) once daily and adjust
according to patient's needs
- Do not give this product IV.
- Give at same time each day (usually at bedtime) and do not mix with any other insulin product.
- Store in refrigerator at 2°8° C (36°46° F), may store at room temperature, 15°30°
C (59°86° F). Discard opened refrigerated vials after 28 d and unrefrigerated vials after 14 d. Do not expose
to excessive heat or sunlight, and do not freeze.
Adverse Effects (≥1%)Body as a Whole:
Allergic reactions. Endocrine: Hypoglycemia
, hypokalemia. Skin:
Injection site reaction, lipodystrophy, pruritus, rash.
InteractionsDrug: oral antidiabetic agents
, ace inhibitors
, disopyramide, fluoxetine, mao inhibitors
, propoxyphene, salicylates
, sulfonamide antibiotics
may enhance hypoglycemia; corticosteroids
, niacin, danazol, diuretics
, sympathomimetic agents
, thyroid hormones
, isoniazid, somatropin
may decrease hypoglycemic effects; beta-blockers
, clonidine, lithium, alcohol
may either potentiate or weaken effects of insulin; pentamidine
may cause hypoglycemia
followed by hyperglycemia. Herbal: Garlic, ginseng
may potentiate hypoglycemic effects.
Slowly absorbed from SC injection site. Onset:
34 h. Duration:
10.424 h. Metabolism:
In liver to active metabolites.
Assessment & Drug Effects
- Monitor for S&S of hypoglycemia (see Appendix F), especially after changes in insulin dose or type.
- Lab tests: Monitor fasting blood glucose and HbA1C periodically.
- Withhold drug and notify physician if patient is hypokalemic.
Patient & Family Education
- Do not inject into areas with redness, swelling, itching, or dimpling.
- Absorption patterns for this drug are not dependent on the injection site.
- Ingest some form of sugar (e.g., orange juice, dissolved table sugar, honey) if symptoms of hypoglycemia develop; and seek
- Check blood sugar as prescribed; notify physician of fasting blood glucose <80 and >120 mg/dL.
- Notify the physician of any of the following: fever, infection, trauma, diarrhea, nausea, or vomiting. Dosage adjustment
may be needed.
- Do not take any other medication unless approved by physician.